Business context and reporting period
Entity mismatch: The request identifies Decoy Therapeutics Inc., but the supplied filing is Salarius Pharmaceuticals, Inc. (ticker SLRX), a clinical-stage oncology company. This is its Form 10-K for the fiscal year ended December 31, 2021, filed March 25, 2022; it is not a quarterly filing.
Salarius was developing seclidemstat (SP-2577), an LSD1 inhibitor in Phase 1/2 trials, and reported SP-3164 as an investigational molecular glue in IND-enabling studies. It had no approved products and no product sales.
Financial performance and liquidity
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Grant revenue | $1.84 million | $5.23 million |
| Research and development expense | $8.55 million | $6.91 million |
| General and administrative expense | $6.10 million | $6.11 million |
| Net loss | $12.77 million | $7.35 million |
| Net loss attributable to common stockholders | $12.77 million | $7.75 million |
| Basic and diluted loss per share | $0.31 | $0.50 |
| Cash used in operating activities | $10.20 million | $10.31 million |
| Cash and cash equivalents at year-end | $29.21 million | $11.12 million |
Revenue was entirely from the CPRIT grant, not product sales. The decline reflected reaching the maximum eligible spending reimbursable from CPRIT. R&D expense rose with increased staffing, clinical enrollment costs, laboratory materials and nonclinical work; lower manufacturing costs partially offset the increase. The 2020 common-stockholder loss exceeded net loss because of a warrant-modification item.
At year-end, working capital was $28.1 million, total liabilities were $2.11 million, and no note payable remained outstanding. Financing activities provided $28.30 million, including $27.29 million of net equity proceeds and $1.49 million from warrant exercises. The company reported an accumulated deficit of $32.20 million. No meaningful product gross margin was reported.
Material changes versus the prior period
- Net loss increased from $7.35 million to $12.77 million, while grant revenue fell by $3.39 million.
- Cash increased by $18.10 million, primarily from equity financing; common shares issued rose to 45.24 million at year-end from 23.81 million a year earlier.
- Seclidemstat reached its recommended Phase 2 dose in 2021, and the company began expanding its Ewing sarcoma program to include FET-translocated sarcomas. An investigator-initiated SP-2577 trial with azacitidine for MDS/CMML also began.
Outlook, risks and unusual items
Management expected continued significant operating losses and higher R&D spending, with no product revenue anticipated until a candidate is approved and commercialized. It said substantial additional capital would be required and that existing cash might not fund operations through one year from the filing date. The auditor’s report included an explanatory paragraph on substantial doubt about the company’s ability to continue as a going concern. Further financing was not assured and could dilute shareholders or require unfavorable debt terms, partnerships or licensing.
In January 2022, after year-end, Salarius acquired assets related to DRX-164, renamed SP-3164, for $1.5 million cash and one million common shares, plus potential milestone and royalty payments. The filing said transaction costs would be expensed in 2022 as acquired in-process R&D. A company director also had consulting and employment ties to the seller’s organization.
Other notable risks include uncertain clinical safety and efficacy, trial-enrollment and regulatory delays, reliance on contract manufacturers and other third parties, dependence on CPRIT funding, and potential COVID-19 disruption. Nasdaq had notified the company of a minimum-bid-price deficiency; the filing reported a March 18, 2022 closing price of $0.39 and a May 16, 2022 compliance deadline. Management stated disclosure controls and internal control over financial reporting were effective at year-end; the auditor was not engaged to audit internal controls.
Investor verification priorities
- Confirm that this Salarius Pharmaceuticals filing is the intended filing, given the Decoy Therapeutics name in the request.
- Review the going-concern disclosure, cash runway assumptions and subsequent financing activity.
- Verify clinical-trial status, enrollment, safety findings and timing for SP-2577 and SP-3164; development claims and outlook are forward-looking.
- Check the full terms, related-party implications and 2022 accounting for the SP-3164 acquisition, including contingent milestones and royalties.
- Confirm CPRIT grant collections, remaining obligations and any potential repayment or revenue-sharing exposure.
- Check the company’s Nasdaq bid-price compliance and current capitalization, including dilution from equity offerings and warrants.